Augtyro (repotrectinib capsules) — Cigna
Non-small cell lung cancer (NSCLC)
Initial criteria
- Patient is age ≥ 18 years; AND
- Patient has locally advanced or metastatic disease; AND
- Patient has ROS1-positive non-small cell lung cancer; AND
- The mutation was detected by an approved test
Approval duration
1 year